GlassScriptPhysician profile
Alex Pavon
NPI 1700819208
$3,066.01
in general payments reported to CMS, 2019-2025
20 companies · $629 in 2025
The $629 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.43 · 2020: $165 · 2021: $426 · 2022: $743 · 2023: $644 · 2024: $417 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,489.03 | 2019-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $292.67 | 2021-2024 | |
| Abbvie INC. | $269.26 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.69 | 2021-2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $143.01 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Novo Nordisk INC | $141.94 | 2019-2023 | Ozempic, Rybelsus |
| Revance Therapeutics, INC. | $128.88 | 2025 | Daxxify |
| Exact Sciences Corporation | $65.66 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $63.87 | 2022-2024 | Freestyle Libre |
| Amgen INC. | $54.80 | 2021-2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $44.32 | 2023-2025 | Farxiga, Airsupra |
| Pfizer INC. | $43.05 | 2023-2024 | |
| Galderma Laboratories, L.P. | $38.54 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.50 | 2022 | |
| Allergan, INC. | $36.50 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.51 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $14.72 | 2021 | |
| Merck Sharp & Dohme LLC | $14.48 | 2020 | |
| Smith+Nephew, INC. | $13.46 | 2021 | |
| Genentech USA, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Pavon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.